

IBD, IL-23, AND INFLAMMATION, OH MY!

Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD



Thursday, February 6, 2025

6:00 PM PT Dinner/Registration

6:30–8:00 PM PT Presentation

San Francisco Marriott Marquis
Room Golden Gate B



IBD, IL-23, AND INFLAMMATION, OH MY!

Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD



Activity Description

In this CME Outfitters live symposium, expert faculty will instruct learners on the role of pro-inflammatory cytokines in the pathogenesis of IBD. Learners will be guided on the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis and how to appraise the clinical implications of anti-IL-23 agents used in the treatment of IBD. Faculty will model the development of individualized treatment plans for patients with IBD that are eligible for treatment with an IL-23-targeted agent.

Target Audience

Gastroenterologists, gastroenterology fellows/trainees, physician associates (PAs), nurse practitioners (NPs), and nurses

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Faculty

Corey A. Siegel

MD, MS (Moderator)

Bincy P. Abraham

MD, MS, AGAF, FACG, FASGE, FCCF

Marita Kametas

MSN, APN, FNP-BC, CMSRN, COCN

Uma Mahadevan

MD

Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Identify the role of pro-inflammatory cytokines in driving inflammation in the pathogenesis of IBD
- Evaluate the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis
- Appraise the clinical implications of anti-IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23-producing cells
- Develop individualized treatment plans for patients with IBD that are eligible for treatment with an IL-23-targeted agent

IBD, IL-23, AND INFLAMMATION, OH MY!

Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD



Accreditation



Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC)

This activity is designated for 1.5 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 1.5 Contact Hours.



PAs (AAPA)

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



RCP Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.



MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Certificate of Participation

This activity was certified for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™].

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.



ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

IBD, IL-23, AND INFLAMMATION, OH MY!

Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD



Faculty



Corey A. Siegel, MD, MS (Moderator)

Director, Center for Digestive Health
Section Chief, Gastroenterology and Hepatology
Dartmouth Hitchcock Medical Center
Constantine and Joyce Hampers Professor of Medicine
Geisel School of Medicine at Dartmouth
Hanover, NH

DISCLOSURES

Dr. Siegel reports the following financial relationships:

Advisory Board: AbbVie Inc.; Bristol Myers Squibb Company; Buhlmann; Janssen Pharmaceuticals, Inc.; Lilly; Napo Therapeutics; Pfizer Inc.; Prometheus Biosciences, Inc.; Roivant Sciences; Takeda Pharmaceuticals U.S.A., Inc.; and Trellus Health Inc.

Consultant: AbbVie Inc.; Boomerang; Bristol Myers Squibb Company; Buhlmann; Janssen Pharmaceuticals, Inc.; Pfizer Inc; Prometheus Biosciences, Inc.; Prometheus Labs; and Takeda Pharmaceuticals U.S.A., Inc.

Grants: AbbVie Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer Inc.

Other financial or material support: Dr. Corey Siegel is co-founder of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.

Corey A. Siegel, MD, MS, is the Director of the Center for Digestive Health, Section Chief of Gastroenterology and Hepatology, and the Co-Director of the Inflammatory Bowel Disease (IBD) Center at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth. Dr. Siegel attended college at Tufts University and then received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as Chief Medical Resident. He then completed a fellowship in gastroenterology at Dartmouth Hitchcock followed by a fellowship in IBD at Massachusetts General Hospital in Boston.

Dr. Siegel's research interests include understanding risk-benefit tradeoffs in IBD, developing models to predict outcomes in Crohn's disease, creating tools to facilitate shared decision-making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ), the Crohn's and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel has lectured nationally and internationally and published numerous journal articles and book chapters on this and other topics in IBD. He is the founder of the BRIDGe group, an international research collaboration of IBD investigators, and is currently the co-chair of the Crohn's and Colitis Foundation Quality of Care Program (IBD Qorus). Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

IBD, IL-23, AND INFLAMMATION, OH MY!

Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD



Faculty



Bincy P. Abraham, MD, MS, AGAF, FACG, FASGE, FCCF

Professor of Clinical Medicine, Houston Methodist Academic Institute

Professor of Clinical Medicine, Weill Cornell Medical College

Adjunct Professor of Clinical Education, Texas A&M University, College of Medicine

Director, Gastroenterology Fellowship Program, Houston Methodist

Distinguished Professor and Director, Underwood Center - Fondren Inflammatory Bowel Disease Program

Houston Methodist Gastroenterology Associates

Houston, TX

Bincy P. Abraham, MD, MS, AGAF, FACG, FASGE, FCCF, is the Distinguished Professor and Director of the Fondren Inflammatory Bowel Disease Program at the Underwood Digestive Diseases Center of Houston Methodist Hospital in Texas. She also serves as the Program Director for the Gastroenterology Fellowship at Houston Methodist Hospital. She earned her medical degree from the University of Texas Medical Branch in Galveston, where she continued with residency training in internal medicine and a fellowship in gastroenterology. During fellowship, she received specialized training in inflammatory bowel disease (IBD) and earned a master's degree in Clinical Investigation.

Dr. Abraham completed a National Visiting Fellow Inflammatory Bowel Disease Rotation program through the Crohn's and Colitis Foundation at Cedars-Sinai Hospital in Los Angeles, California. She has chaired the Southern Regional chapter of the CCGA Medical Advisory Committee, served as President of the Texas Gulf Coast Gastroenterology Society, and is involved in national committees for and is a Fellow of the American College of Gastroenterology, the American Gastroenterology Association, the American Society of Gastrointestinal Endoscopy, and the Crohn's and Colitis Foundation. She is trained in and passionate about intestinal ultrasound in IBD patient care.

DISCLOSURES

Dr. Abraham reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb; Celltrion Inc.; Johnson & Johnson; Lilly; Medtronic; Pfizer Inc.; Prometheus Laboratories; Samsung Bioepis; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc.; Bristol Myers Squibb; Johnson & Johnson; Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

IBD, IL-23, AND INFLAMMATION, OH MY!

Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD



Faculty



Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN

Inflammatory Bowel Disease Advanced Practice Nurse
Manager of Gastroenterology Advanced Practice Provider Services
The University of Chicago Medicine
Chicago, IL

Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN, is a family nurse practitioner and ostomy specialist who treats adult patients with inflammatory bowel disease (IBD). She serves as the manager for the Advanced Practice Gastroenterology Service at the University of Chicago in Illinois. She volunteers her time as a mentor for the Crohn's and Colitis Advanced Practice Provider (APP) mentorship program and delivers empowering lectures to APPs to optimize their care of patients with IBD. She was awarded the honor of Distinguished APP of 2023 at the University of Chicago. She is currently pursuing a doctorate in nursing practice and a master's degree in public health at Johns Hopkins University in Baltimore, Maryland with an emphasis on diversity, equity, and inclusion.

DISCLOSURES

Ms. Kametas reports the following financial relationships:

Advisory Board: Lilly and Pfizer Inc.

Consultant: TKG Therapeutics, Inc.

Grants: GI Research Foundation

Speakers Bureau: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Pfizer Inc.

IBD, IL-23, AND INFLAMMATION, OH MY!

Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD



Faculty



Uma Mahadevan, MD

Lynne and Marc Benioff Professor of Gastroenterology
Director, Colitis and Crohn's Disease Center
Director, Advanced IBD Fellowship
Division of Gastroenterology, Department of Medicine
University of California San Francisco
San Francisco, CA

DISCLOSURES

Dr. Mahadevan reports the following financial relationships:

Advisory Board: Data Safety Monitoring Board (DSMB): Merck & Co., Inc.

Consultant: AbbVie Inc.; Bristol Myers Squibb; Boehringer Ingelheim; Celltrion Inc; Enveda Biosciences; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc; Protagonist Therapeutics Inc.; Rani Therapeutics; Roivant Sciences; and Takeda Pharmaceuticals U.S.A., Inc.

Grants: The Leona M. and Harry B. Helmsley Charitable Trust

Uma Mahadevan, MD, is the Lynne and Marc Benioff Professor of Gastroenterology, Director of the Colitis and Crohn's Disease Center, and Director of the Advanced IBD Fellowship at the University of California San Francisco (UCSF). She completed her medical degree at the State University of New York in Brooklyn, her residency in internal medicine at Mount Sinai Medical Center in New York, her fellowship in gastroenterology at UCSF, and her Advanced Fellowship in IBD at the Mayo Clinic in Rochester, Minnesota. For her exceptional work in pregnancy and drug safety and her mentoring of GI fellows and junior faculty, she received the American Gastroenterological Association (AGA) 2022 Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) Section Research Mentor Award and the 2022 Sherman Prize.

Dr. Mahadevan is a fellow of the AGA, for whom she was Chair for the IMIBD Section, Chair of the AGA National IBD Parenthood Initiative, and Director (2023) and Co-Director (2022, 2017) of the AGA Postgraduate Course. She is a fellow of the American College of Gastroenterology and served on the Educational Affairs Committee and as a member of the Advanced IBD Fellow Curriculum Committee. She is an inaugural councilor at the ASGE Artificial Intelligence Institute for Gastroenterology. She was Chair of the Crohn's Colitis Foundation Clinical Research Grants committee, a member of the National Scientific Advisory Committee and Taskforce on Women in IBD, and Co-Chair of the annual Crohn's Colitis Congress (2020). Dr. Mahadevan is a member of the International Organization of IBD (IOIBD) and serves on the nominating committee.

Dr. Mahadevan is a global expert on the management of pregnancy and drug safety in patients with IBD. She chairs the Helmsley Global Consensus on Management of Pregnancy in IBD (2024) and the joint AGA and Society of Maternal Fetal Medicine Clinical Care Pathway on the Management of IBD in Pregnancy (2019). She is interested in the role of diet in IBD and has an ongoing original study in this area. Her current projects include a national prospective registry of pregnancy outcomes and drug safety in women with IBD on immunosuppressive and biologic medications (PIANO) and a clinical trial on the impact of nutritional interventions in the management of IBD (SEAMUS). She has an interest in digital health and led the transition of the GI division to telemedicine at the start of the pandemic in March 2020, and developed an IBD chatbot with the Center for Digital Health and Innovation at UCSF as well as the IBD Smartnote.

Dr. Mahadevan has served on many prestigious journals, including special section editor for *Gastroenterology*. She is proud to have mentored several Advanced IBD Fellows who now hold key roles in IBD centers across the United States.

IBD, IL-23, AND INFLAMMATION, OH MY!

Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD



Disclosure Declarations

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Peer Reviewers

Thai Nguyen, MD, MHA—no disclosures to report.

Shirley Michelle Franks, MSN, APRN, FNP-BC—no disclosures to report.

CMEO Staff/Planners

Keshia Pitt, PhD—no disclosures to report.

Chelsey Goins, PhD—no disclosures to report.

Scott J. Hershman, MD, FACEHP, CHCP—no disclosures to report.

Sandra Caballero, PharmD—no disclosures to report.

Sharon Tordoff—no disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

IBD, IL-23, AND INFLAMMATION, OH MY!

Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD



Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty. Please see additional information below.

ASK FACULTY A QUESTION

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

VIEW AND TAKE NOTES ON PRESENTATION SLIDES

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to create an account.



Downloadable Resources

Downloadable resources will be available at cmeoutfitters.com/ohmyresources.

Engage with Us

Follow us [@cmeoutfitters](https://twitter.com/cmeoutfitters) for announcements about upcoming CME opportunities, health care news, and more!

Thank you for joining us today!

CLOSING GAPS IN CARE FOR

Short Bowel Syndrome in the Community Setting



**Book a Live or Virtual
Grand Rounds Today!**

Available January 2025–March 2025

CME OUTFITTERS 

Contact **Moriah Aponte**
apontem@cmeoutfitters.com